
Opinion|Videos|February 14, 2025
MCL Therapy Selection and Sequencing
Panelists discuss the treatment- and patient-specific factors considered when determining induction therapy for treatment-naive patients with mantle cell lymphoma (MCL), including the decision between aggressive and less aggressive approaches, and how prior therapy exposure influences subsequent treatment sequencing for MCL.
Advertisement
Episodes in this series

- What treatment- and patient-specific factors do you consider when determining induction therapy for a treatment-naive patient with MCL (eg, aggressive vs less aggressive)?
- How do you sequence therapies for patients with MCL and how does prior therapy exposure influence your subsequent choice of treatments?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
4
Flow Cytometry Tool Could Improve Treatment Monitoring in MS
5